- Home
- RC vs CMPS Comparison
RC vs CMPS Comparison
Compare RC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- CMPS
- Stock Information
- Founded
- RC 2007
- CMPS 2020
- Country
- RC United States
- CMPS United Kingdom
- Employees
- RC N/A
- CMPS N/A
- Industry
- RC Real Estate Investment Trusts
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- RC Real Estate
- CMPS Health Care
- Exchange
- RC Nasdaq
- CMPS Nasdaq
- Market Cap
- RC 517.6M
- CMPS 598.7M
- IPO Year
- RC N/A
- CMPS 2020
- Fundamental
- Price
- RC $3.05
- CMPS $6.33
- Analyst Decision
- RC Hold
- CMPS Strong Buy
- Analyst Count
- RC 5
- CMPS 8
- Target Price
- RC $6.10
- CMPS $16.57
- AVG Volume (30 Days)
- RC 2.3M
- CMPS 1.6M
- Earning Date
- RC 11-07-2025
- CMPS 11-04-2025
- Dividend Yield
- RC 16.39%
- CMPS N/A
- EPS Growth
- RC N/A
- CMPS N/A
- EPS
- RC N/A
- CMPS N/A
- Revenue
- RC N/A
- CMPS N/A
- Revenue This Year
- RC N/A
- CMPS N/A
- Revenue Next Year
- RC $141.93
- CMPS N/A
- P/E Ratio
- RC N/A
- CMPS N/A
- Revenue Growth
- RC N/A
- CMPS N/A
- 52 Week Low
- RC $3.02
- CMPS $2.25
- 52 Week High
- RC $7.64
- CMPS $7.09
- Technical
- Relative Strength Index (RSI)
- RC 25.78
- CMPS 53.83
- Support Level
- RC $3.05
- CMPS $6.20
- Resistance Level
- RC $3.22
- CMPS $6.87
- Average True Range (ATR)
- RC 0.10
- CMPS 0.40
- MACD
- RC -0.00
- CMPS -0.07
- Stochastic Oscillator
- RC 6.00
- CMPS 33.48
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.